Diagnostic Value of Ischemia-Modified Albumin in Terms of Acute Coronary Syndromes in Chronic Renal Patients Admitted to Emergency Department with Chest Pain and/or Equivalent Symptoms

This study aimed to reveal the diagnostic value of Ischemia-Modified Albumin (IMA) in terms of acute coronary syndromes in chronic renal patients admitted to emergency department with chest pain and equivalent symptoms. Methods: Our study is a descriptive cross-sectional research and included 125 chronic renal patients admitted to emergency department with chest pain and/or equivalent symptoms and 96 healthy volunteers as the control group. Results: In our study, acute coronary syndrome (ACS) was detected in 12 (9.6%) of the patients. Mean IMA level was 0.720.17 absorbance units (ABSU) in the group with Chronic renal disease (CRD)+ACS, 0.710.16 ABSU in patients with CRD but without ACS, and 0.470.14 ABSU in the control group. A statistically significant difference was found between the groups. While no difference between chronic renal patients in whom ACS developed and chronic renal patients in whom ACS did not develop was recorded in terms of IMA. IMA value of both patients with CRD and chronic renal patients in whom ACS developed was significantly higher than that of the healthy control group. In our study, no correlation was found between troponin levels and IMA. Conclusion: IMA level increases in both CRD and ACS. Therefore, it was determined that IMA level did not significantly increase although ACS developed depending on already high IMA level in patients with CRD. We believe IMA cannot be safely used for the diagnosis of ACS in patients with CRD due to the low specificity rate and absence of an optimal threshold value.